Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Eisai

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Eisai's 2012 sales performance.

Eisai Co., Ltd.

Biogen and Eisai announce FDA submission for early Alzheimer’s treatment

Biogen and Eisai announce FDA submission for early Alzheimer’s treatment

Dependent upon the results of this analysis, Eisai may submit for full approval at some point this year. ... Alzheimer’s disease is a progressive and devastating disease with few treatment options,” said Haruo Naito, chief executive officer at Eisai.

Biogen retracts EMA application for Alzheimer's drug Aduhelm

Biogen retracts EMA application for Alzheimer's drug Aduhelm compound.”. In an online statement, Biogen has said that it ‘will continue to advocate for patients and remains committed to research and development, as well as to its collaboration with Eisai,

Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment

Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment The crucial study assessed the combination of Lenvima (lenvatinib) – a multiple receptor tyrosine kinase inhibitor administered orally as a pill, discovered by Eisai – with Merck’s anti-PD-1 therapy Keytruda ... advanced endometrial carcinoma,"

Five years needed to confirm the benefit of Aduhelm

Five years needed to confirm the benefit of Aduhelm Biogen and Eisai have announced plans for a global, phase 3 clinical trial to confirm the long-term clinical benefit of Aduhelm treatment against Alzheimer’s disease. ... Few experts question that Biogen and Eisai’s monoclonal antibody Aduhelm

Eisai/Biogen present more data on antibody for Alzheimer’s disease

Eisai/Biogen present more data on antibody for Alzheimer’s disease This week, Eisai and Biogen presented a new sensitivity analysis at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, Massachusetts, based on an open-label extension. ... Eisai and Biogen have also presented some insights around the

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....